⌘K
t
N4 Pharma plc announced on 16 January 2025 the release of an investor Q&A featuring Dr Alastair Smith, a Non-Executive Director who recently joined the company's Board. The Q&A is now live on N4 Pharma's interactive investor hub.
| Date | 16 Jan 2025 |
| Time | 07:00:08 |
| Category | Miscellaneous |
| ID | 4811T |
16 January 2025
N4 Pharma plc
("N4 Pharma" or the "Company")
N4 Pharma Non-Executive Director Q&A
N4 Pharma plc (AIM: N4P), the biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce the release of an investor Q&A with Dr Alastair Smith, Non-Executive Director, who recently joined the Board of the Company.
The Q&A is now live on N4 Pharma's interactive investor hub here: https://investors.n4pharma.com/link/mPqEEP
- Ends -
For more information please contact:
|
N4 Pharma plc Nigel Theobald, Chief Executive Officer Luke Cairns, Executive Director
Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub |
Via N4 Pharma Investor Hub Sign up at investors.n4pharma.com
|
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) |
Tel: +44 (0) 20 3470 0470 |
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker/James Pope |
Tel: +44 (0) 20 3657 0050 |
|
Northstar Communications Limited Investor Relations Sarah Hollins |
Tel: +44 (0) 113 730 3896
|
About N4 Pharma
N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.
N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform. With an estimated 10 million people globally suffering from Crohn's disease and ulcerative colitis, the IBD treatment market was worth $20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over $27.6bn by 2030, driven by both increased incidences of the disease and development of new treatments.
For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.